|
1
|
Cheppalli V and Nikhilesh A: A review on
lesch-nyhan syndrome: A rare inherited disorder with
hypoxanthine-guanine phosphoribosyltransferase deficiency. Int J
Pharm Sci Rev Res. 78:92–99. 2023.
|
|
2
|
Reisz JA, Dzieciatkowska M, Stephenson D,
Gamboni F, Morton DH and D'Alessandro A: Red blood cells from
individuals with Lesch-Nyhan syndrome: Multi-omics insights into a
novel S162N mutation causing Hypoxanthine-guanine
phosphoribosyltransferase deficiency. Antioxidants (Basel).
12(1699)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nanagiri A and Shabbir N: Lesch-nyhan
syndrome: In: StatPearls. StatPearls Publishing, Treasure Island,
FL, 2024.
|
|
4
|
Torres RJ and Puig JG:
Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency:
Lesch-Nyhan syndrome. Orphanet J Rare Dis. 2(48)2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Baumeister AA and Frye GD: The biochemical
basis of the behavioral disorder in the Lesch-Nyhan syndrome.
Neurosci Biobehav Rev. 9:169–178. 1985.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wurtele SK, King AC and Drabman RS:
Treatment package to reduce SIB in a Lesch-Nyhan patient. J Ment
Defic Res. 28:227–234. 1984.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Momosaki K, Kido J, Matsumoto S, Taniguchi
A, Akiyama T, Sawada T, Ozasa S and Nakamura K: The Effect of
S-Adenosylmethionine treatment on neurobehavioral phenotypes in
Lesch-Nyhan disease: A case report. Case Rep Neurol. 11:256–264.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Christie R, Bay C, Kaufman IA, Bakay B,
Borden M and Nyhan WL: Lesch-Nyhan disease: Clinical experience
with nineteen patients. Dev Med Child Neurol. 24:293–306.
1982.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sampat R, Fu R, Larovere LE, Torres RJ,
Ceballos-Picot I, Fischbach M, de Kremer R, Schretlen DJ, Puig JG
and Jinnah HA: Mechanisms for phenotypic variation in Lesch-Nyhan
disease and its variants. Hum Genet. 129:71–78. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Camici M, Micheli V, Ipata PL and Tozzi
MG: Pediatric neurological syndromes and inborn errors of purine
metabolism. Neurochem Int. 56:367–378. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fu R, Sutcliffe D, Zhao H, Huang X,
Schretlen DJ, Benkovic S and Jinnah HA: Clinical severity in
Lesch-Nyhan disease: The role of residual enzyme and compensatory
pathways. Mol Genet Metab. 114:55–61. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cakmakli HF, Torres RJ, Menendez A,
Yalcin-Cakmakli G, Porter CC, Puig JG and Jinnah HA: Macrocytic
anemia in Lesch-Nyhan disease and its variants. Genet Med.
21:353–360. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nyhan WL: Clinical features of the
Lesch-nyhan syndrome. Arch Intern Med. 130:186–192. 1972.PubMed/NCBI
|
|
14
|
Del Bene VA, Crawford JL, Gomez-Gastiasoro
A, Vannorsdall TD, Buchholz A, Ojeda N, Harris JC, Jinnah HA and
Schretlen DJ: Microstructural white matter abnormalities in
Lesch-Nyhan disease. Eur J Neurosci. 55:264–276. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Schretlen DJ, Varvaris M, Ho TE,
Vannorsdall TD, Gordon B, Harris JC and Jinnah HA: Regional brain
volume abnormalities in Lesch-Nyhan disease and its variants: A
cross-sectional study. Lancet Neurol. 12:1151–1158. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fasullo M and Endres L: Nucleotide salvage
deficiencies, DNA damage and neurodegeneration. Int J Mol Sci.
16:9431–9449. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Krajewski O, Opielka M, Urbanowicz K,
Chojnowski K, Kochany P, Pawlowski K, Tomaszewska J, Peters GJ,
Smoleński RT and Bełdzińska MM: Management of neurological symptoms
in Lesch-Nyhan disease: A systematic review. Neurosci Biobehav Rev.
165(105847)2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Visser JE, Bar PR and Jinnah HA:
Lesch-Nyhan disease and the basal ganglia. Brain Res Brain Res Rev.
32:449–475. 2000.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Olson L and Houlihan D: A review of
behavioral treatments used for Lesch-Nyhan syndrome. Behav Modif.
24:202–222. 2000.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jang G, Shin HR, Do HS, Kweon J, Hwang S,
Kim S, Heo SH, Kim Y and Lee BH: Therapeutic gene correction for
Lesch-Nyhan syndrome using CRISPR-mediated base and prime editing.
Mol Ther Nucleic Acids. 31:586–595. 2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Fu R, Ceballos-Picot I, Torres RJ,
Larovere LE, Yamada Y, Nguyen KV, Hegde M, Visser JE, Schretlen DJ,
Nyhan WL, et al: Genotype-phenotype correlations in neurogenetics:
Lesch-Nyhan disease as a model disorder. Brain. 137:1282–1303.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ceballos-Picot I, Le Dantec A, Brassier A,
Jais JP, Ledroit M, Cahu J, Ea HK, Daignan-Fornier B and Pinson B:
New biomarkers for early diagnosis of Lesch-Nyhan disease revealed
by metabolic analysis on a large cohort of patients. Orphanet J
Rare Dis. 10(7)2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jinnah HA, Visser JE, Harris JC, Verdu A,
Larovere L, Ceballos-Picot I, Gonzalez-Alegre P, Neychev V, Torres
RJ, Dulac O, et al: Delineation of the motor disorder of
Lesch-Nyhan disease. Brain. 129:1201–1217. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vinokurov AY, Soldatov VO, Seregina ES,
Dolgikh AI, Tagunov PA, Dunaev AV, Skorkina MY, Deykin AV and
Abramov AY: HPRT1 deficiency induces alteration of mitochondrial
energy metabolism in the brain. Mol Neurobiol. 60:3147–3157.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Jinnah HA, Ceballos-Picot I, Torres RJ,
Visser JE, Schretlen DJ, Verdu A, Laróvere LE, Chen CJ, Cossu A, Wu
CH, et al: Attenuated variants of Lesch-Nyhan disease. Brain.
133:671–689. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
ThinkGenetic Foundation: Lesch-nyhan
syndrome. https://thinkgenetic.org/diseases/lesch-nyhan-syndrome/.
Accessed July 17, 2024.
|
|
27
|
Mak BS, Chi CS, Tsai CR, Lee WJ and Lin
HY: New mutations of the HPRT gene in Lesch-Nyhan syndrome. Pediatr
Neurol. 23:332–335. 2000.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nguyen KV, Naviaux RK and Nyhan WL: Novel
mutation in the human HPRT1 gene and the Lesch-Nyhan disease.
Nucleosides Nucleotides Nucleic Acids. 36:704–711. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang D, Zhao J, Teng J, Li W, Zhao X and
Li L: Genetic analysis of a Chinese pedigree with Lesch-Nyhan
syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 40:723–726.
2023.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
30
|
Li L, Qiao X, Liu F, Wang J, Shen H, Fu H
and Mao JH: Description of the molecular and phenotypic spectrum of
Lesch-nyhan disease in eight chinese patients. Front Genet.
13(868942)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ogasawara N, Stout JT, Goto H, Sonta S,
Matsumoto A and Caskey CT: Molecular analysis of a female
Lesch-Nyhan patient. J Clin Invest. 84:1024–1027. 1989.PubMed/NCBI View Article : Google Scholar
|
|
32
|
van Bogaert P, Ceballos I, Desguerre I,
Telvi L, Kamoun P and Ponsot G: Lesch-Nyhan syndrome in a girl. J
Inherit Metab Dis. 15:790–791. 1992.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yukawa T, Akazawa H, Miyake Y, Takahashi
Y, Nagao H and Takeda E: A female patient with Lesch-Nyhan
syndrome. Dev Med Child Neurol. 34:543–546. 1992.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Yamada Y, Goto H, Yukawa T, Akazawa H and
Ogasawara N: Molecular mechanisms of the second female Lesch-Nyhan
patient. Adv Exp Med Biol. 370:337–340. 1994.PubMed/NCBI View Article : Google Scholar
|
|
35
|
De Gregorio L, Nyhan WL, Serafin E and
Chamoles NA: An unexpected affected female patient in a classical
Lesch-Nyhan family. Mol Genet Metab. 69:263–268. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Sebesta I, Stiburkova B, Dvorakova L,
Hrebicek M, Minks J, Stolnaja L, Vernerova Z and Rychlik I: Unusual
presentation of Kelley-seegmiller syndrome. Nucleosides Nucleotides
Nucleic Acids. 27:648–655. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Aral B, de Saint Basile G, Al-Garawi S,
Kamoun P and Ceballos-Picot I: Novel nonsense mutation in the
hypoxanthine guanine phosphoribosyltransferase gene and nonrandom
X-inactivation causing Lesch-Nyhan syndrome in a female patient.
Hum Mutat. 7:52–58. 1996.PubMed/NCBI View Article : Google Scholar
|
|
38
|
AlBakheet A, AlQudairy H, Alkhalifah J,
Almoaily S, Kaya N and Rahbeeni Z: Detailed genetic and clinical
analysis of a novel de novo variant in HPRT1: Case report of a
female patient from Saudi Arabia with Lesch-Nyhan syndrome. Front
Genet. 13(1044936)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Hooft C, Van Nevel C and De Schaepdryver
AF: Hyperuricosuric encephalopathy without hyperuricaemia. Arch Dis
Child. 43:734–737. 1968.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sekine M, Fujiwara M, Okamoto K, Ichida K,
Nagata K, Hille R and Nishino T: Significance and amplification
methods of the purine salvage pathway in human brain cells. J Biol
Chem. 300(107524)2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Guibinga GH, Murray F, Barron N, Pandori W
and Hrustanovic G: Deficiency of the purine metabolic gene HPRT
dysregulates microRNA-17 family cluster and guanine-based cellular
functions: A role for EPAC in Lesch-Nyhan syndrome. Hum Mol Genet.
22:4502–4515. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lopez JM, Outtrim EL, Fu R, Sutcliffe DJ,
Torres RJ and Jinnah HA: Physiological levels of folic acid reveal
purine alterations in Lesch-Nyhan disease. Proc Natl Acad Sci USA.
117:12071–12079. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Saito Y and Takashima S: Neurotransmitter
changes in the pathophysiology of Lesch-Nyhan syndrome. Brain Dev.
22 (Suppl 1):S122–S131. 2000.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bell S, Kolobova I, Crapper L and Ernst C:
Lesch-Nyhan syndrome: Models, theories, and therapies. Mol
Syndromol. 7:302–311. 2016.PubMed/NCBI View Article : Google Scholar
|
|
45
|
van der Zee SP, Schretlen ED and Monnens
LA: Megaloblastic anaemia in the Lesch-Nyhan syndrome. Lancet.
1(1427)1968.PubMed/NCBI View Article : Google Scholar
|
|
46
|
McKeran RO: Factors in the pathogenesis of
the brain damage and anaemia in the Lesch-Nyhan syndrome. Ciba
Found Symp. 83–96. 1977.PubMed/NCBI View Article : Google Scholar : doi:
10.1002/9780470720301.ch6.
|
|
47
|
Nemkov T, Sun K, Reisz JA, Song A, Yoshida
T, Dunham A, Wither MJ, Francis RO, Roach RC, Dzieciatkowska M, et
al: Hypoxia modulates the purine salvage pathway and decreases red
blood cell and supernatant levels of hypoxanthine during
refrigerated storage. Haematologica. 103:361–372. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Laróvere LE, Escuredo E, Becerra A and
Dodelson de Kremer R: Lesch-nyhan disease and its variants:
Phenotypic and mutation spectrum of hypoxanthine-guanine
phosphoribosyltransferase deficiency in argentine patients. J
Inborn Errors Metab: 9, 2021
doi:10.1590/2326-4594-jiems-2020-0027.
|
|
49
|
Saugstad OD: Hypoxanthine as a measurement
of hypoxia. Pediatr Res. 9:158–161. 1975.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Saugstad OD: Hypoxanthine as an indicator
of hypoxia: Its role in health and disease through free radical
production. Pediatr Res. 23:143–150. 1988.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Roussel C, Morel A, Dussiot M, Marin M,
Colard M, Fricot-Monsinjon A, Martinez A, Chambrion C, Henry B,
Casimir M, et al: Rapid clearance of storage-induced
microerythrocytes alters transfusion recovery. Blood.
137:2285–2298. 2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ceballos-Picot I, Mockel L, Potier MC,
Dauphinot L, Shirley TL, Torero-Ibad R, Fuchs J and Jinnah HA:
Hypoxanthine-guanine phosphoribosyl transferase regulates early
developmental programming of dopamine neurons: Implications for
Lesch-Nyhan disease pathogenesis. Hum Mol Genet. 18:2317–2327.
2009.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Lewers JC, Ceballos-Picot I, Shirley TL,
Mockel L, Egami K and Jinnah HA: Consequences of impaired purine
recycling in dopaminergic neurons. Neuroscience. 152:761–772.
2008.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Mastrangelo L, Kim JE, Miyanohara A, Kang
TH and Friedmann T: Purinergic signaling in human pluripotent stem
cells is regulated by the housekeeping gene encoding hypoxanthine
guanine phosphoribosyltransferase. Proc Natl Acad Sci USA.
109:3377–3382. 2012.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Cuttler K, Hassan M, Carr J, Cloete R and
Bardien S: Emerging evidence implicating a role for neurexins in
neurodegenerative and neuropsychiatric disorders. Open Biol.
11(210091)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Ghaffar A, Akhter T, Stromme P, Misceo D,
Khan A, Frengen E, Umair M, Isidor B, Cogné B, Khan AA, et al:
Variants of NAV3, a neuronal morphogenesis protein, cause
intellectual disability, developmental delay, and microcephaly.
Commun Biol. 7(831)2024.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Ignacio DA, Babikian T, Dennis EL, Bickart
KC, Choe M, Snyder AR, Brown A, Giza CC and Asarnow RF: The
neurocognitive correlates of DTI indicators of white matter
disorganization in pediatric moderate-to-severe traumatic brain
injury. Front Hum Neurosci. 18(1470710)2024.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Guibinga GH, Hrustanovic G, Bouic K,
Jinnah HA and Friedmann T: MicroRNA-mediated dysregulation of
neural developmental genes in HPRT deficiency: Clues for
Lesch-Nyhan disease? Hum Mol Genet. 21:609–622. 2012.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Kang TH, Park Y, Bader JS and Friedmann T:
The housekeeping gene hypoxanthine guanine
phosphoribosyltransferase (HPRT) regulates multiple developmental
and metabolic pathways of murine embryonic stem cell neuronal
differentiation. PLoS One. 8(e74967)2013.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Guibinga GH: MicroRNAs: Tools of
mechanistic insights and biological therapeutics discovery for the
rare neurogenetic syndrome Lesch-Nyhan disease (LND). Adv Genet.
90:103–131. 2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Sutcliffe DJ, Dinasarapu AR, Visser JE,
Hoed JD, Seifar F, Joshi P, Ceballos-Picot I, Sardar T, Hess EJ,
Sun YV, et al: Induced pluripotent stem cells from subjects with
Lesch-Nyhan disease. Sci Rep. 11(8523)2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Bortolotti M, Polito L, Battelli MG and
Bolognesi A: Xanthine oxidoreductase: One enzyme for multiple
physiological tasks. Redox Biol. 41(101882)2021.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Abramov AY, Scorziello A and Duchen MR:
Three distinct mechanisms generate oxygen free radicals in neurons
and contribute to cell death during anoxia and reoxygenation. J
Neurosci. 27:1129–1138. 2007.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Pinto CS and Seifert R: Decreased
GTP-stimulated adenylyl cyclase activity in HPRT-deficient human
and mouse fibroblast and rat B103 neuroblastoma cell membranes. J
Neurochem. 96:454–459. 2006.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Gray M, Nash KR and Yao Y: Adenylyl
cyclase 2 expression and function in neurological diseases. CNS
Neurosci Ther. 30(e14880)2024.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Arhakis A, Topouzelis N, Kotsiomiti E and
Kotsanos N: Effective treatment of self-injurious oral trauma in
Lesch-Nyhan syndrome: A case report. Dent Traumatol. 26:496–500.
2010.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Lee J, Lee E, Shin J, Kim S and Jeong T:
Semi-fixed lip bumper in lesch-nyhan syndrome: An interim treatment
modality. J Korean Acad Pediatr Dent. 47:93–98. 2020.
|
|
68
|
Dabrowski E, Smathers SA, Ralstrom CS,
Nigro MA and Leleszi JP: Botulinum toxin as a novel treatment for
self-mutilation in Lesch-Nyhan syndrome. Dev Med Child Neurol.
47:636–639. 2005.PubMed/NCBI
|
|
69
|
Garcia-Romero MDM, Torres RJ, Garcia-Puig
J and Pascual-Pascual SI: Safety and efficacy of botulinum toxin in
the treatment of Self-biting behavior in Lesch-nyhan disease.
Pediatr Neurol. 127:6–10. 2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Gottle M, Prudente CN, Fu R, Sutcliffe D,
Pang H, Cooper D, Veledar E, Glass JD, Gearing M, Visser JE and
Jinnah HA: Loss of dopamine phenotype among midbrain neurons in
Lesch-Nyhan disease. Ann Neurol. 76:95–107. 2014.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Lloyd KG, Hornykiewicz O, Davidson L,
Shannak K, Farley I, Goldstein M, Shibuya M, Kelley WN and Fox IH:
Biochemical evidence of dysfunction of brain neurotransmitters in
the Lesch-Nyhan syndrome. N Engl J Med. 305:1106–1111.
1981.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Wong DF, Harris JC, Naidu S, Yokoi F,
Marenco S, Dannals RF, Ravert HT, Yaster M, Evans A, Rousset O, et
al: Dopamine transporters are markedly reduced in Lesch-Nyhan
disease in vivo. Proc Natl Acad Sci USA. 93:5539–5543.
1996.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Visser JE, Schretlen DJ, Bloem BR and
Jinnah HA: Levodopa is not a useful treatment for Lesch-Nyhan
disease. Mov Disord. 26:746–749. 2011.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Jankovic J, Caskey TC, Stout JT and Butler
IJ: Lesch-Nyhan syndrome: A study of motor behavior and
cerebrospinal fluid neurotransmitters. Ann Neurol. 23:466–469.
1988.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Watts RW, Spellacy E, Gibbs DA, Allsop J,
McKeran RO and Slavin GE: Clinical, post-mortem, biochemical and
therapeutic observations on the Lesch-Nyhan syndrome with
particular reference to the Neurological manifestations. Q J Med.
51:43–78. 1982.PubMed/NCBI
|
|
76
|
Montero C, Smolenski RT, Duley JA and
Simmonds HA: S-adenosylmethionine increases erythrocyte ATP in
vitro by a route independent of adenosine kinase. Biochem
Pharmacol. 40:2617–2623. 1990.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Glick N: Dramatic reduction in self-injury
in Lesch-Nyhan disease following S-adenosylmethionine
administration. J Inherit Metab Dis. 29(687)2006.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Dolcetta D, Parmigiani P, Salmaso L,
Bernardelle R, Cesari U, Andrighetto G, Baschirotto G, Nyhan WL and
Hladnik U: Quantitative evaluation of the clinical effects of
S-adenosylmethionine on mood and behavior in Lesch-Nyhan patients.
Nucleosides Nucleotides Nucleic Acids. 32:174–188. 2013.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Elion GB, Benezra FM, Beardmore TD and
Kelley WN: Studies with allopurinol in patients with impaired renal
function. Adv Exp Med Biol. 122A:263–267. 1980.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Daudon M: Crystalluria. Nephrol Ther:
174-190, 2015 (In French).
|
|
81
|
Sriranganathan MK, Vinik O, Pardo Pardo J,
Bombardier C and Edwards CJ: Interventions for tophi in gout.
Cochrane Database Syst Rev. 8(CD010069)2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Greene ML, Fujimoto WY and Seegmiller JE:
Urinary xanthine stones-a rare complication of allopurinol therapy.
N Engl J Med. 280:426–427. 1969.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Simmonds HA, Reiter S, Davies PM and
Cameron JS: Orotidine accumulation in human erythrocytes during
allopurinol therapy: Association with high urinary
oxypurinol-7-riboside concentrations in renal failure and in the
Lesch-Nyhan syndrome. Clin Sci (Lond). 80:191–197. 1991.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Krauss JK, Lipsman N, Aziz T, Boutet A,
Brown P, Chang JW, Davidson B, Grill WM, Hariz MI, Horn A, et al:
Technology of deep brain stimulation: Current status and future
directions. Nat Rev Neurol. 17:75–87. 2021.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Lozano AM, Lipsman N, Bergman H, Brown P,
Chabardes S, Chang JW, Matthews K, McIntyre CC, Schlaepfer TE,
Schulder M, et al: Deep brain stimulation: Current challenges and
future directions. Nat Rev Neurol. 15:148–160. 2019.PubMed/NCBI View Article : Google Scholar
|
|
86
|
van Westen M, Rietveld E, Bergfeld IO, de
Koning P, Vullink N, Ooms P, Graat I, Liebrand L, van den Munckhof
P, Schuurman R and Denys D: Optimizing deep brain stimulation
parameters in Obsessive-compulsive disorder. Neuromodulation.
24:307–315. 2021.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Pycroft L, Stein J and Aziz T: Deep brain
stimulation: An overview of history, methods, and future
developments. Brain Neurosci Adv.
2(2398212818816017)2018.PubMed/NCBI View Article : Google Scholar
|
|
88
|
McIntyre CC, Savasta M, Kerkerian-Le Goff
L and Vitek JL: Uncovering the mechanism(s) of action of deep brain
stimulation: Activation, inhibition, or both. Clin Neurophysiol.
115:1239–1248. 2004.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Javed N and Cascella M: Neuroanatomy,
Globus Pallidus. Publishing ISITIFS, editor, 2023.
|
|
90
|
Taira T, Kobayashi T and Hori T:
Disappearance of self-mutilating behavior in a patient with
lesch-nyhan syndrome after bilateral chronic stimulation of the
globus pallidus internus. Case report. J Neurosurg. 98:414–416.
2003.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Piedimonte F, Andreani JC, Piedimonte L,
Micheli F, Graff P and Bacaro V: Remarkable clinical improvement
with bilateral globus pallidus internus deep brain stimulation in a
case of Lesch-Nyhan disease: Five-year follow-up. Neuromodulation.
18:118–122. 2015.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Llargues-Sistac G, Bonjoch L and
Castellvi-Bel S: HAP1, a new revolutionary cell model for gene
editing using CRISPR-Cas9. Front Cell Dev Biol.
11(1111488)2023.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Anzalone AV, Koblan LW and Liu DR: Genome
editing with CRISPR-Cas nucleases, base editors, transposases and
prime editors. Nat Biotechnol. 38:824–844. 2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Gaudelli NM, Komor AC, Rees HA, Packer MS,
Badran AH, Bryson DI and Liu DR: Programmable base editing of A•T
to G•C in genomic DNA without DNA cleavage. Nature. 551:464–471.
2017.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Khasnavis T, Torres RJ, Sommerfeld B, Puig
JG, Chipkin R and Jinnah HA: A double-blind, placebo-controlled,
crossover trial of the selective dopamine D1 receptor antagonist
ecopipam in patients with Lesch-Nyhan disease. Mol Genet Metab.
118:160–166. 2016.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Lauber M, Plecko B, Pfiffner M, Nuoffer JM
and Haberle J: The Effect of S-Adenosylmethionine on
Self-mutilation in a patient with Lesch-nyhan disease. JIMD Rep.
32:51–57. 2017.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Gutierrez C, Pellene A and Micheli F:
Botulinum toxin: Treatment of self-mutilation in patients with
Lesch-Nyhan syndrome. Clin Neuropharmacol. 31:180–183.
2008.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Zecavati N, Santos C and Oyegbile T:
Botulinum toxin for the treatment of Extra-pyramidal symptoms of
Lesch-nyhan syndrome (P6.252). Neurology. 84(252)2015.
|
|
99
|
Gilbert C, Sauer M and Cheng J: Reduction
of self-mutilating behavior and improved oromotor function in a
patient with Lesch-Nyhan syndrome following botulinum toxin
injection: A case report. J Pediatr Rehabil Med. 14:133–136.
2021.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Chen BC, Balasubramaniam S, McGown IN,
O'Neill JP, Chng GS, Keng WT, Ngu LH and Duley JA: Treatment of
Lesch-Nyhan disease with S-adenosylmethionine: Experience with five
young Malaysians, including a girl. Brain Dev. 36:593–600.
2014.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Pralong E, Pollo C, Coubes P, Bloch J,
Roulet E, Tetreault MH, Debatisse D and Villemure JG:
Electrophysiological characteristics of limbic and motor globus
pallidus internus (GPI) neurons in two cases of Lesch-Nyhan
syndrome. Neurophysiol Clin. 35:168–173. 2005.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Cif L, Biolsi B, Gavarini S, Saux A,
Robles SG, Tancu C, Vasques X and Coubes P: Antero-ventral internal
pallidum stimulation improves behavioral disorders in Lesch-Nyhan
disease. Mov Disord. 22:2126–2129. 2007.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Deon LL, Kalichman MA, Booth CL, Slavin KV
and Gaebler-Spira DJ: Pallidal deep-brain stimulation associated
with complete remission of self-injurious behaviors in a patient
with Lesch-Nyhan syndrome: A case report. J Child Neurol.
27:117–120. 2012.PubMed/NCBI View Article : Google Scholar
|
